期刊文献+

机体对HPV L1免疫应答的研究进展 被引量:1

Immune responses to major capsid protein L1 of human papillomavirus
下载PDF
导出
摘要 HPV L1相关的免疫应答是天然免疫和适应性免疫协同作用的结果,目前相关的研究已经渗入了免疫应答的全过程。天然免疫参与HPV L1诱导的免疫应答,但人们对它的认识仍然很有限。适应性免疫研究的进展主要体现在3方面:①识别阶段。HPV的相关抗原主要由DC和LC摄取、加工、处理,经胞质溶胶、交叉提呈两种提呈途径提呈给CD8+细胞并使其致敏。②增殖分化阶段。Th1和Th2细胞都有出现,表明HPV L1不仅介导体液免疫,也介导细胞免疫。③效应阶段。L1介导产生的IgG、IgA、IgM类抗体都有其特殊性。 The associated immune responses to HPV L1 are the synergetic result of innate immunity and adaptive immunity,and now the research of this field has extended into every part of immune response process.Innate immunity contributes to the immune responses to HPV L1,but now its knowledge is still very limited.On the contrary,the research of adaptive has got great achievement.It has been confirmed that in recognization phase,HPV associated antigens are mainly uptaken and processed by DC and LC,and then presents to naive CD8+ cells through cytosal and cross presentation pathways for priming the naive CD8+ cells.During the following phases of proliferation and differentiation,both Th1 and Th2 cells are differentiated,suggesting that HPV L1 can induce not only humoral immunity but also cellular immunity.In effector phase,the features of IgG,IgA,and IgM mediated by L1 have been further investigated.
机构地区 三峡大学医学院
出处 《免疫学杂志》 CAS CSCD 北大核心 2006年第z1期51-54,59,共5页 Immunological Journal
基金 湖北省教育厅重大课题(99Z009) 湖北省卫生厅项目(2002JX1B111)资助
关键词 HPV L1 天然免疫 适应性免疫 HPV L1 Innate immunity Adaptive immunity
  • 相关文献

参考文献23

  • 1[1]Womack SD,Chirenje ZM,Gaffikin L,et al.HPV-based cervical cancer screening in a population at high risk for HIV infecion[J].Int J Cancer,2000,85 (2):206-210.
  • 2[2]Yang R,Murillo FM,Cui H,et al.Papillomavirus-Like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Thl immune responses via MyD88[J].Virol,2004,78 (20):11 152-11 160.
  • 3[3]Bontkes HJ,Rnizendaal JJ,Kramer D,et al.Plasmacytoid dendritic cells are present in cervical carcinoma and become activated by human papillomavirus type 16 virus-like particles[ J].Gynecol Oncol,2005,96 (3):897-901.
  • 4[4]Pinto LA,Castle PE,Roden RB,et al.HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood[J].Vaccine,2005,23 (27):3 555-3 564.
  • 5[5]Yan M,Peng J,Jabbar LA,et al.Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake,both cells cross-prime T cells[J].Virology,2004,324 (2):297-310.
  • 6[6]Drobni P,Mistry N,McMillan N,et al.Carboxy-fluorescein diacetate,succinimidyl ester labeled papillomavirus virus-like particles fluoresce after internalization and interact with heparan sulfate for binding and entry[J].Virology,2003,310(1):163-172.
  • 7[7]Turan T,Kalantari M,Calleja Macias IE,et al.Methylation of the human papillomavirus-18 L1 gene:A biomarker of neoplastic progression?[ J].Virology,2006,349(1):175 -183.
  • 8[8]Moron VG,Rueda P,Sedlik C,et al.In vivo,dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway[ J ].J Immunol,2003,171 (5):2 242-2 250.
  • 9[9]Fausch SC,Da Silva DM,Kast WM,et al.Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and kangerhans cells[J].Cancer Res,2003,63 (13):3478-3482.
  • 10[10]Berry JM,Palefsky JM.A review of human papillomavirus vaccines:from basic science to clinical trials[J].Front Biosci,2003,8 (Suppl):333-345.

同被引文献17

  • 1张艳,李宁丽.人类乳头瘤病毒免疫致病机制[J].现代免疫学,2006,26(6):523-526. 被引量:15
  • 2[2]Parkin DM,Pisani P,Ferlay J.Estimates of the worldwide incidence of 25 major cancers in 1990[J].Int J Cancer,1999,80(6):827-841.
  • 3[3]Walboomers JM,Jacobs MV,Munoz N,et al.Human papil lomavirus is a necessary cause of invasive cervical cancer worldwide[J].J Pathol,1999,189(1):12-19.
  • 4[5]Modis Y,Trus BL,Harrison SC.Atomic model of the papil lomavirus capsid[J].EMBO J,2002,21(18):4754-4762.
  • 5[8]Brown DR,Fife KH,Wheeler CM,et al.Early assessment of the efficacy of a human papillomavirus type 16 LI virus-like particle vaccine[J].Vaccine,2004,22(21/22):2936-2942.
  • 6[9]Keam SJ,Harper DM.Human papillomavirus types 16 and 18 vaccine(recombinant,ASM adjuvanted,adsorbed)[Cer varix][J].Drugs,2008,68(3):359-372.
  • 7[10]Huang CM.Human papillomavirus and vaccination[J].Mayo Clin Proc,2008,83(6):701-706.
  • 8[11]Villa J,Munoz N,Perez G,et al.Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV(types 6/11/16/18)vaccine clinical trials[J].Curr Med Res Opin,2008,24(6):1623-1634.
  • 9[12]Cason J,Patel D,McCance DJ,et al.Identification of im munogenic regions of the major coat protein of human papillo mavirus type 16 that contain type-restricted epitopes[J].J Gen Virol,1989,70(Pt11):2973-2987.
  • 10[13]Midler M,Gausepohl H,de Martynoff G,et al.Identification of seroreactive regions of the human papillomavirus type 16 proteins E4,E6,E7 and LI[J].J Gen Virol,1990,71(10):2709-2717.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部